logo-loader
viewVolitionRx

VolitionRx unveils promising proof-of-concept data for leukemia and lymphoma tests

A pre-clinical Nu.Q. assay – VolitionRx’s flagship cancer detection test – detected 80% of newly-diagnosed non-Hodgkins lymphoma in its latest study

VolitionRx -
Headquartered in Isnes, Belgium, VolitionRx is developing easy to use blood-based cancer tests to accurately diagnose a range of cancers

VolitionRx Limited (NYSEAMERICAN:VNRX) said Tuesday that results from its latest proof of concept study show that a single pre-clinical Nu.Q cancer-test assay boasts an impressive ability to detect with accuracy non-Hodgkins lymphoma (NHL) and other types of leukemia.

Using a microtiter plate platform, one pre-clinical Nu.Q. assay – VolitionRx’s flagship cancer detection test – detected 80% of newly-diagnosed non-Hodgkins lymphoma and a mix of leukemia cases (including acute lymphocytic leukemia and acute myeloid leukemia) at 95%. The area under the curve (AUC) for this single assay was 91%, the company said.

“This is a very exciting outcome as we continue the development of our assays beyond colorectal, lung and prostate cancer,” said Dr. Jake Micallef, chief scientific officer with VolitionRx. “We have previously announced results from both single assay and panels of Nu.Q biomarkers but the results of this discovery study are the best single Nu.Q. assay result in any cancer we have demonstrated to date.”

READ: VolitionRx boosts its balance sheet in third quarter, strengthens its product pipeline

As part of the study, blood plasma samples were taken from 62 healthy volunteers with a mean age of 45, as well as 300 patients previously diagnosed with bladder, bone, brain, esophageal, melanoma, skin, uterine and cervical cancers with a mean age of 56; 54 subjects diagnosed with hematopoietic stem cell cancers with a mean age of 57 also participated.

Looking ahead, VolitionRx hopes to evaluate its latest findings in larger clinical trials of “symptomatic” populations.

“There are over 700,000 new cases of NHL, ALL and AML diagnosed globally each year and approximately 415,000 deaths,” concluded Dr. Jason Terrell, chief medical officer with VolitionRx. “Whilst clearly more studies need to be conducted, we hope that a routine blood test using our Nu.Q technology could lead to earlier diagnosis.”

Headquartered in Isnes, Belgium, VolitionRx is developing easy to use blood-based cancer tests to accurately diagnose a range of cancers. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by Volition’s Nu.Q platform.

Quick facts: VolitionRx

Price: 4.48 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $184.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 5 days ago

2 min read